You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed Hodgkin's disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma Trial in New York (Isatuximab, Standard Procedures)

Recruiting
  • Lymphoma
  • +3 more
  • New York, New York
    Columbia University
Apr 27, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Feb 1, 2023

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Caba (Evaluation of

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • Evaluation of therapeutical approach after ASCT
  • Caba, Argentina
    FUNDALEU
Oct 1, 2021

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Stanford, California
    Stanford University
Jun 21, 2022

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Lymphoma, Non-Hodgkin, Hodgkin Lymphoma Trial in Worldwide (AZD3470)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Miami, Florida
  • +10 more
Nov 13, 2023

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022